Immunome Inc. (IMNM) stock
IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$18.77+0.07 (+0.37%)
Close on Nov 13, 2026Market cap $2.13BP/E –Yield –
Immunome enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Immunome's enterprise value was $1.58B on Nov 11, 2026, against $1.42B a year earlier. Over the last 5 years it ranged from -$3.95M to $2.52B, with a median of $410.00M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.58B | -7.2% |
| 2025 | Dec 31, 2025 | $1.70B | +322.7% |
| 2024 | Dec 31, 2024 | $401.55M | +905.7% |
| 2023 | Dec 29, 2023 | $39.93M | – |
| 2022 | Dec 30, 2022 | -$276.02K | -100.3% |
| 2021 | Dec 31, 2021 | $100.49M | +2064.6% |
| 2020 | Dec 31, 2020 | $4.64M | – |
See a number that looks wrong?